MCID: MNN020
MIFTS: 43

Meningococcal Infection malady

Categories: Rare diseases, Infectious diseases

Aliases & Classifications for Meningococcal Infection

Aliases & Descriptions for Meningococcal Infection:

Name: Meningococcal Infection 50
Meningococcal Infections 41 69

Classifications:



External Ids:

ICD10 33 A39

Summaries for Meningococcal Infection

MedlinePlus : 41 meningococci are a type of bacteria that cause serious infections. the most common infection is meningitis, which is an inflammation of the thin tissue that surrounds the brain and spinal cord. meningococci can also cause other problems, including a serious bloodstream infection called sepsis. meningococcal infections can spread from person to person. risk factors include age - it is more common in infants, teens, and young adults living in close quarters, such as in college dorms or military settings certain medical conditions, such as not having a spleen travel to areas where meningococcal disease is common in its early stages, you may have flu-like symptoms and a stiff neck. but the disease can progress quickly and can be fatal. early diagnosis and treatment are extremely important. lab tests on your blood and cerebrospinal fluid can tell if you have it. treatment is with antibiotics. since the infection spreads from person to person, family members may also need to be treated. a vaccine can prevent meningococcal infections.

MalaCards based summary : Meningococcal Infection, also known as meningococcal infections, is related to myocardial infarction and waterhouse-friderichsen syndrome, and has symptoms including fever and pruritus. An important gene associated with Meningococcal Infection is C7 (Complement C7), and among its related pathways/superpathways are G-protein signaling G-Protein alpha-i signaling cascades and Calcium signaling pathway. The drugs Ciprofloxacin and Vaccines have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and spleen, and related phenotypes are cardiovascular system and growth/size/body region

Related Diseases for Meningococcal Infection

Diseases related to Meningococcal Infection via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 53)
id Related Disease Score Top Affiliating Genes
1 myocardial infarction 28.5 ADD1 ADRB1 ADRB2 AGT AGTR1
2 waterhouse-friderichsen syndrome 11.4
3 neisseria meningitidis infection 11.3
4 meningitis 11.2
5 complement factor h deficiency 10.8
6 properdin deficiency, x-linked 10.8
7 tendinopathy 10.2 G6PD SOD1
8 subacute monocytic leukemia 10.2 G6PD GSR
9 choriodal dystrophy, central areolar 2 10.1 ROM1 TTR
10 tenosynovitis 10.1 G6PD GSR SOD1
11 epithelial malignant thymoma 10.1 ADRB1 ADRB2
12 setariasis 10.1 G6PD SOD1
13 penile cancer, childhood 10.0 ADD1 AGT
14 meningococcal meningitis 10.0
15 myositis fibrosa 10.0 AGTR1 SOD1
16 disseminated intravascular coagulation 9.9
17 iris disease 9.9 AGT AGTR1
18 prostate neuroendocrine neoplasm 9.9 AGT AGTR1
19 preaxial polydactyly of fingers 9.9 AGT AGTR1
20 cascade stomach 9.9 AGT AGTR1
21 chronic myocardial ischemia 9.9 AGT SOD1 TTR
22 hyperuricemic nephropathy, familial juvenile 2 9.9 AGT AGTR1
23 eye degenerative disease 9.9 AGT AGTR1
24 complement deficiency 9.9
25 cetp-related hyperalphalipoproteinemia 9.9 AGT AGTR1
26 critical limb ischemia 9.9 ADRB1 ADRB2 AGTR1
27 eastern equine encephalitis 9.8 AGT AGTR1
28 pericarditis 9.8
29 flat umbilicus familial 9.8 AGT AGTR1
30 malaria 9.7
31 hepatitis 9.7
32 bacterial meningitis 9.7
33 meningococcemia 9.7
34 mucositis 9.7
35 properdin deficiency 9.7
36 agammaglobulinemia 6 9.7 AGT AGTR1
37 cerebritis 9.6
38 systemic lupus erythematosus 9.6
39 acquired immunodeficiency syndrome 9.6
40 thyroiditis 9.6
41 septic arthritis 9.6
42 c7 deficiency 9.6
43 myocarditis 9.6
44 c5 deficiency 9.6
45 lupus erythematosus 9.6
46 arthritis 9.6
47 iridocyclitis 9.6
48 hepatitis b 9.6
49 thrombocytopenia 9.6
50 pharyngitis 9.6

Graphical network of the top 20 diseases related to Meningococcal Infection:



Diseases related to Meningococcal Infection

Symptoms & Phenotypes for Meningococcal Infection

UMLS symptoms related to Meningococcal Infection:


fever, pruritus

MGI Mouse Phenotypes related to Meningococcal Infection:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.76 ADRB1 ADRB2 AGT AGTR1 G6PD GSR
2 growth/size/body region MP:0005378 9.56 ADD1 ADRB1 ADRB2 AGT AGTR1 CPB2
3 homeostasis/metabolism MP:0005376 9.28 ADD1 ADRB1 ADRB2 AGT AGTR1 CPB2

Drugs & Therapeutics for Meningococcal Infection

Drugs for Meningococcal Infection (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 65)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
2 Vaccines Phase 4,Phase 3,Phase 2,Phase 1
3 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1
4 Antibodies Phase 4,Phase 3,Phase 2,Phase 1
5
Lactitol Phase 4,Phase 3,Phase 2 585-86-4 3871
6 Adjuvants, Immunologic Phase 4,Phase 2,Phase 3,Phase 1
7 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
8 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 3,Phase 2
9 Anti-Bacterial Agents Phase 4,Phase 3
10 Anti-Infective Agents Phase 4,Phase 3,Phase 1
11 Laxatives Phase 4,Phase 3,Phase 2
12 MF59 oil emulsion Phase 4
13 Cathartics Phase 4,Phase 3,Phase 2
14 Complement Factor H Phase 4
15 Cytochrome P-450 CYP1A2 Inhibitors Phase 4
16 Cytochrome P-450 Enzyme Inhibitors Phase 4
17 Topoisomerase Inhibitors Phase 4
18 BCG Vaccine Phase 4
19 histidine Nutraceutical Phase 4
20
Iron Approved Phase 3,Phase 2 7439-89-6 23925
21
Acetaminophen Approved Phase 3 103-90-2 1983
22
Tetracycline Approved, Vet_approved Phase 3 60-54-8 5353990
23
Edetic Acid Approved, Vet_approved Phase 3,Phase 2 60-00-4, 62-33-9 6049
24
Aluminum hydroxide Approved Phase 2, Phase 3,Phase 1 21645-51-2
25 Analgesics Phase 3
26 Chelating Agents Phase 3,Phase 2
27 Complement System Proteins Phase 3
28 Analgesics, Non-Narcotic Phase 3
29 PENTA Phase 3,Phase 2
30 Pentetic Acid Phase 3,Phase 2
31 Peripheral Nervous System Agents Phase 3
32 Antacids Phase 2, Phase 3,Phase 1
33 Pharmaceutical Solutions Phase 3,Phase 2,Phase 1
34 Fibrinolytic Agents Phase 3,Phase 2
35 Anticoagulants Phase 3,Phase 2
36 Protective Agents Phase 3,Phase 2
37 Antidotes Phase 3,Phase 2
38 Iron Chelating Agents Phase 3,Phase 2
39 Anti-Ulcer Agents Phase 2, Phase 3,Phase 1
40 Antipyretics Phase 3,Phase 2
41 Iron-Dextran Complex Phase 3
42 Krestin Phase 3
43
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754 657311
44
Formaldehyde Approved, Vet_approved Phase 2 50-00-0 712
45
Butyric Acid Experimental Phase 2 107-92-6 264
46 fondaparinux Phase 2
47 Cortisol succinate Phase 2
48 Hydrocortisone 17-butyrate 21-propionate Phase 2
49 Hydrocortisone acetate Phase 2
50 Hydrocortisone-17-butyrate Phase 2

Interventional clinical trials:

(show top 50) (show all 299)
id Name Status NCT ID Phase
1 Kinetic of Immune Memory Response After Re-Vaccination With Meningococcal Vaccine Unknown status NCT00262015 Phase 4
2 Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age Completed NCT00310635 Phase 4
3 Immunogenicity of the Booster Dose of Two MenC Vaccines Completed NCT00392808 Phase 4
4 Safety and Immunogenicity of Intradermal Versus Subcutaneous Doses of Menomune® Completed NCT00850603 Phase 4
5 Persistence of Antibodies and Kinetics of B Cell Response in Healthy Children After Vaccination With MCC Vaccine Completed NCT00310713 Phase 4
6 Kinetics of B Cell Response in Infants Menjugate Vaccination Completed NCT00310700 Phase 4
7 Persistence of Antibody Response to N. Meningitidis Group C in Children Completed NCT00316654 Phase 4
8 Persistence of Immune Response After Vaccination With MCC Completed NCT00310687 Phase 4
9 Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines Completed NCT01270503 Phase 4
10 Descriptive, Post-marketing, Surveillance Safety Study of Menactra Vaccine Completed NCT00254995 Phase 4
11 Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose Completed NCT01823536 Phase 4
12 Can we Reduce the Number of Vaccine Injections for Children? Completed NCT01129518 Phase 4
13 Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier Completed NCT02633787 Phase 4
14 US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease Completed NCT00282295 Phase 4
15 Understanding the Immune Response to Two Different Meningitis Vaccines Completed NCT01593514 Phase 4
16 Study to Evaluate the Immune Response of United Kingdom (UK) Infants Receiving DTaP/Hib/IPV, Meningococcal C Conjugate and Pneumococcal Conjugate Vaccines, Antibody Persistence and Responses to Booster Doses in the Second Year of Life Completed NCT00625677 Phase 4
17 Response of United Kingdom (UK) Infants to a Reduced Primary Schedule With Meningococcal C and Pneumococcal Conjugate Vaccines Completed NCT00197808 Phase 4
18 Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects Completed NCT02591290 Phase 4
19 Study of Sanofi Pasteur and Lanzhou Institute's Meningococcal (Group A and C) Polysaccharide Vaccine in Children Completed NCT01430611 Phase 4
20 Safety of Purified Meningococcal Vaccine With Serogroups ACWY, in 3,000 Filipino Subjects Aged > 2 Years Completed NCT00290329 Phase 4
21 Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age Completed NCT01659996 Phase 4
22 Study on the Impact of Vaccination With a Conjugate Vaccine on Meningococcal Carriage Completed NCT01119482 Phase 4
23 Assess the Non-inferiority of GSK Biologicals' Mencevax™ ACWY (Manufactured by a New Process) vs Mencevax™ ACWY (the Already Existing Vaccine in the Market) When Given as a Single Dose to Subjects Aged 2-30 Yrs Completed NCT00227422 Phase 4
24 Hepatitis B Vaccination in Infants Completed NCT01896596 Phase 4
25 Study Evaluating the Safety and Ability to Produce Immune Response of Prevenar and Meningitec Given at the Same Time Completed NCT00581035 Phase 4
26 Fractional Dose Tetravalent A, C, Y, W135 Meningococcal Polysaccharide Vaccine Completed NCT00271479 Phase 4
27 A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents Completed NCT01424644 Phase 4
28 Evaluation of Meningococcal C Vaccine Programmes in Canadian Children Completed NCT00936962 Phase 4
29 Effectiveness Assessment of Vaccinating Schoolchildren Against Influenza Completed NCT01693380 Phase 4
30 Maternal Flu Vaccine Trial in Bamako, Mali Completed NCT01430689 Phase 4
31 MF59-adjuvanted Influenza Vaccine and 23-valent Pneumococcal Polysaccharide Vaccine Completed NCT02225327 Phase 4
32 A Phase IV Study to Evaluate the Immunogenicity and Safety in UK Laboratory Workers of Menitorix Completed NCT00503165 Phase 4
33 Pertussis and Meningitis C Concomitant Vaccination in Adolescents Completed NCT02526394 Phase 4
34 Typhoid Vi Vaccine Effectiveness in Hechi, Guangxi, China Completed NCT00131833 Phase 4
35 Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine Completed NCT00777257 Phase 4
36 Concomitant Use of Hepatitis A Vaccine, Inactivated With Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Given to Healthy Children 15 Months of Age (V251-068) Completed NCT00289913 Phase 4
37 Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A Vaccines Completed NCT02601040 Phase 4
38 Immunogenicity and Safety of PCV13 and Fluad in Adults Aged ≥60 Years Completed NCT02215863 Phase 4
39 Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 Months to 55 Years of Age in the Republic of South Korea Recruiting NCT01766206 Phase 4
40 South Australian Meningococcal B Vaccine Herd Immunity Study Recruiting NCT03089086 Phase 4
41 Postmarketing Surveillance Study for Use of Menactra® in the Republic of Korea Recruiting NCT02864927 Phase 4
42 Investigating the Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba) Active, not recruiting NCT02569632 Phase 4
43 Evaluation of Antibody Persistence Following 4 MenACWY Vaccinations Active, not recruiting NCT02446691 Phase 4
44 Ciprofloxacin for the Prevention of Meningococcal Meningitis Active, not recruiting NCT02724046 Phase 4
45 A Study of the Interaction Between BCG And MenC Immunisation: BAM Active, not recruiting NCT02002156 Phase 4
46 A Trial Comparing Two Pertussis-containing Vaccines in Pregnancy and Vaccine Responses in UK Mothers and Their Infants Active, not recruiting NCT02145624 Phase 4
47 A Study to Evaluate Pharmacists as Immunizers to Improve Coverage and Provider/Recipient Satisfaction Enrolling by invitation NCT02868970 Phase 4
48 Babies Born Early Antibody Response to Men B Vaccination: BEAR Men B Not yet recruiting NCT03125616 Phase 4
49 Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects. Completed NCT02141516 Phase 3
50 A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive. Completed NCT01911221 Phase 3

Search NIH Clinical Center for Meningococcal Infection

Genetic Tests for Meningococcal Infection

Anatomical Context for Meningococcal Infection

MalaCards organs/tissues related to Meningococcal Infection:

39
Testes, Brain, Spleen, Spinal Cord, Skin, Neutrophil, Adrenal Cortex

Publications for Meningococcal Infection

Articles related to Meningococcal Infection:

(show top 50) (show all 246)
id Title Authors Year
1
A Seroepidemiological Study of Serogroup A Meningococcal Infection in the African Meningitis Belt. ( 26872255 )
2016
2
Correction: A Seroepidemiological Study of Serogroup A Meningococcal Infection in the African Meningitis Belt. ( 27379429 )
2016
3
Prevention of Meningococcal Infection in the United States: Current Recommendations and Future Considerations. ( 27449147 )
2016
4
Self Mutilating Behaviour in Severe Meningococcal Infection; An Interesting Association. ( 27437275 )
2016
5
50 Years Ago in TheJournal ofPediatrics: Factors in the Prognosis of Meningococcal Infection: Review of 63 Cases with Emphasis on Recognition and Management of the Severely Ill Patient. ( 26922764 )
2016
6
Prevention of rare diseases: how revolutionary techniques can help vulnerable individuals-the example of serogroup B meningococcal infection. ( 25553243 )
2015
7
Public health risk communication by text message in response to a cluster of invasive meningococcal infection in a primary school. ( 24894450 )
2014
8
The costs associated with the public health management of a cluster of meningococcal infection in England. ( 25173479 )
2014
9
Public health action and mass chemoprophylaxis in response to a small meningococcal infection outbreak at a nursery in the West Midlands, England. ( 23467531 )
2013
10
Invasive meningococcal infection: analysis of 110 cases from a tertiary care centre in North East India. ( 22821284 )
2013
11
Severe meningococcal infection: a review of epidemiology, diagnosis, and management. ( 23830646 )
2013
12
Altered neutrophil counts at diagnosis of invasive meningococcal infection in children. ( 23736141 )
2013
13
Patterns of meningococcal infection in Sudan with emergence of Neisseria meningitidis serogroup W135. ( 24313147 )
2013
14
Pachymeningitis after meningococcal infection. ( 23642701 )
2013
15
Genetic susceptibility to meningococcal infection. ( 23409824 )
2013
16
Management of a rifampicin-resistant meningococcal infection in a teenager. ( 23408002 )
2013
17
Diagnosis of meningococcal infection by QPCR: detection and quantification of DNA / Neisseria meningitidis. ( 23272547 )
2012
18
Thyroid hormone enhances nitric oxide-mediated bacterial clearance and promotes survival after meningococcal infection. ( 22844479 )
2012
19
A teenager with meningococcal infection. ( 21999443 )
2011
20
The burden of hospitalizations for meningococcal infection in Spain (1997-2008). ( 21664402 )
2011
21
Real-time impedance analysis of host cell response to meningococcal infection. ( 21078346 )
2011
22
Disseminated intravascular coagulation, meningococcal infection, and ischemic changes affecting the lower extremities: a case study. ( 20619693 )
2010
23
Can near real-time monitoring of emergency department diagnoses facilitate early response to sporadic meningococcal infection?--prospective and retrospective evaluations. ( 20979656 )
2010
24
Complement factor 7 gene mutations in relation to meningococcal infection and clinical recurrence of meningococcal disease. ( 19931914 )
2010
25
The influence of genomics and proteomics on the development of potential vaccines against meningococcal infection. ( 20670394 )
2010
26
C7 deficiency and meningococcal infection susceptibility in two spanish families. ( 20591074 )
2010
27
Review of meningococcal infection in children at a United Kingdom hospital. ( 19388559 )
2009
28
Genetic polymorphisms in host response to meningococcal infection: the role of susceptibility and severity genes. ( 19477561 )
2009
29
Hospital admissions for meningococcal infection in Spain (1997-2005). ( 19042024 )
2009
30
Gram staining: an unexplored diagnostic tool for diagnosis of meningococcal infection in the developing world. ( 19176273 )
2009
31
MenACWY-CRM, a novel quadrivalent glycoconjugate vaccine against Neisseria meningitidis for the prevention of meningococcal infection. ( 20072946 )
2009
32
Risk of transmitting meningococcal infection by transient contact on aircraft and other transport. ( 19296869 )
2009
33
Myocardial infarction after meningococcal infection: a potential inflammatory link or a challenging puzzle? ( 17854929 )
2008
34
Two centuries of meningococcal infection: from Vieusseux to the cellular and molecular basis of disease. ( 18927406 )
2008
35
Thrombin-activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children. ( 18021301 )
2008
36
Single nucleotide polymorphisms in genes of circulatory homeostasis in surviving pediatric intensive care patients with meningococcal infection. ( 18679149 )
2008
37
Susceptibility to meningococcal infection--nature versus nurture? ( 18779704 )
2008
38
Mechanisms of defense formation against meningococcal infection in mice immunized with synthetic peptides. ( 18239810 )
2007
39
Transgenic mice expressing human transferrin as a model for meningococcal infection. ( 17893132 )
2007
40
Prognostic utility of the semi-quantitative procalcitonin test, neutrophil count and C-reactive protein in meningococcal infection in children. ( 16249930 )
2006
41
Deficient alternative complement pathway activation due to factor D deficiency by 2 novel mutations in the complement factor D gene in a family with meningococcal infections. ( 16527897 )
2006
42
Clinical spectrum of meningococcal infection in infants younger than six months of age. ( 16642734 )
2006
43
Induction of the antimicrobial peptide CRAMP in the blood-brain barrier and meninges after meningococcal infection. ( 17030578 )
2006
44
Prospects for vaccine prevention of meningococcal infection. ( 16418528 )
2006
45
Risk factors for death from meningococcal infection in Recife, Brazil. ( 16000346 )
2005
46
Waterhouse-Friderichsen syndrome as a result of non-meningococcal infection. ( 14747454 )
2004
47
Pericarditis after meningococcal infection: case report of a child with two distinct episodes. ( 15014314 )
2004
48
Outer membrane vesicles (OMVs) and detoxified lipooligosaccharide (dLOS) obtained from Brazilian prevalent N. meningitidis serogroup B strains protect mice against homologous and heterologous meningococcal infection and septic shock. ( 15193387 )
2004
49
Recurrent pericarditis after meningococcal infection. ( 15247622 )
2004
50
Unusual sequelae of meningococcal infection: a case report of hepatic dysfunction, protracted neurological complications and late cutaneous manifestations associated with serogroup y. ( 12643869 )
2003

Variations for Meningococcal Infection

Expression for Meningococcal Infection

Search GEO for disease gene expression data for Meningococcal Infection.

Pathways for Meningococcal Infection

GO Terms for Meningococcal Infection

Cellular components related to Meningococcal Infection according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.17 AGT C7 CPB2 G6PD GSR SOD1

Biological processes related to Meningococcal Infection according to GeneCards Suite gene sharing:

(show all 26)
id Name GO ID Score Top Affiliating Genes
1 cellular response to oxidative stress GO:0034599 9.7 G6PD GSR SOD1
2 response to cold GO:0009409 9.63 ADRB1 ADRB2
3 activation of adenylate cyclase activity GO:0007190 9.62 ADRB1 ADRB2
4 positive regulation of reactive oxygen species metabolic process GO:2000379 9.62 AGT AGTR1
5 brown fat cell differentiation GO:0050873 9.61 ADRB1 ADRB2
6 positive regulation of cytokine production GO:0001819 9.61 AGT SOD1
7 regulation of vasoconstriction GO:0019229 9.6 AGT AGTR1
8 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.59 ADRB1 ADRB2
9 positive regulation of cellular protein metabolic process GO:0032270 9.58 AGT AGTR1
10 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.58 AGT AGTR1
11 regulation of vasodilation GO:0042312 9.57 ADRB2 AGTR1
12 low-density lipoprotein particle remodeling GO:0034374 9.56 AGT AGTR1
13 negative regulation of multicellular organism growth GO:0040015 9.55 ADRB1 ADRB2
14 cellular sodium ion homeostasis GO:0006883 9.54 AGT C7
15 positive regulation of superoxide anion generation GO:0032930 9.51 AGT SOD1
16 glutathione metabolic process GO:0006749 9.5 G6PD GSR SOD1
17 diet induced thermogenesis GO:0002024 9.49 ADRB1 ADRB2
18 positive regulation of cholesterol esterification GO:0010873 9.48 AGT AGTR1
19 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.46 AGT AGTR1
20 positive regulation of NAD(P)H oxidase activity GO:0033864 9.43 AGT AGTR1
21 renin-angiotensin regulation of aldosterone production GO:0002018 9.4 AGT AGTR1
22 regulation of renal sodium excretion GO:0035813 9.37 AGT AGTR1
23 vasodilation by norepinephrine-epinephrine involved in regulation of systemic arterial blood pressure GO:0002025 9.26 ADRB1 ADRB2
24 heat generation GO:0031649 9.16 ADRB1 ADRB2
25 regulation of blood vessel diameter by renin-angiotensin GO:0002034 8.96 AGT AGTR1
26 positive regulation of extracellular matrix constituent secretion GO:0003331 8.62 AGT CPB2

Molecular functions related to Meningococcal Infection according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein heterodimerization activity GO:0046982 9.56 ADD1 ADRB1 AGTR1 TTR
2 NADP binding GO:0050661 9.32 G6PD GSR
3 adrenergic receptor activity GO:0004935 9.16 ADRB1 ADRB2
4 epinephrine binding GO:0051379 8.96 ADRB1 ADRB2
5 norepinephrine binding GO:0051380 8.62 ADRB1 ADRB2

Sources for Meningococcal Infection

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....